Ancillary and Molecular
Testing Pathways
Caris MI Tumor Seek Hybrid™
This test provides a detailed molecular analysis of cancer by examining DNA, RNA, and proteins. It helps inform personalized treatment decisions, particularly for genitourinary cancers.
Caris Assure™ Therapy Selection
This test offers a non-invasive method to analyze biomarkers from a blood sample, when tissue samples are unavailable. It identifies tumor-derived variants and mutations, aiding in therapy decisions and clinical trial matching.
Prolaris® Prostate Tumor Test
The Prolaris® Prostate Tumor Test by Myriad Genetics is a genetic test used to evaluate the aggressiveness of prostate cancer by analyzing tumor cell activity. This assessment provides a risk score, which helps physicians and patients make more informed, personalized treatment decisions. It is specifically intended for individuals diagnosed with localized prostate cancer to aid in deciding between active surveillance and more immediate therapeutic interventions.
knowerror® system
The knowerror® system is a DNA-confirmation test that ensures biopsy samples are accurately matched to each patient, reducing diagnostic errors in prostate and breast cancer cases. This verification process ensures specimens are free of contamination, adding an extra level of accuracy and confidence in biopsy diagnoses.
UroSeq
The UroSeq test is a molecular diagnostic test designed to detect genetic mutations and alterations in urine samples, helping identify and monitor bladder cancer. It is particularly useful for patients with a history of bladder cancer, offering a non-invasive method for ongoing surveillance and aiding in early detection of recurrence.
Decipher® Prostate Test
The Decipher Prostate Test is a genomic test that evaluates the activity of specific genes in prostate cancer tissue to assess the aggressiveness of the cancer. It provides a risk score that helps guide treatment decisions, particularly in men with localized prostate cancer, by identifying those who may benefit from more intensive treatment or closer monitoring.
MyRisk® Germline Test
The Decipher Prostate Test is a genomic test that evaluates the activity of specific genes in prostate cancer tissue to assess the aggressiveness of the cancer. It provides a risk score that helps guide treatment decisions, particularly in men with localized prostate cancer, by identifying those who may benefit from more intensive treatment or closer monitoring.
The ArteraAI Prostate Test is an artificial intelligence biomarker test that analyzes digital images from prostate biopsies alongside clinical data. It predicts the potential benefits of hormone therapy and estimates long-term outcomes for patients diagnosed with localized prostate cancer who have not previously received hormone therapy. This test helps identify those who may benefit from intensified treatment. With PathNet, results are available in 1-2 days without requiring new tissue samples.
